("Teijin Pharma"; Headquarters: Chiyoda-ku, Tokyo; President: Masaki Taneda), which is responsible for the Teijin Group's healthcare business, will begin supplying renewable energy electricity ("renewable energy") using non-fossil certificates to its Tokyo Research Center on April 1, 2026. The Tokyo Research Center will be supplied with renewable energy from April 1, 2026. This is expected to reduce CO2 emissions at the center by approximately 3,343 tons per year.

Background and Effects of Introduction
The medical and healthcare fields are an essential part of the social infrastructure that supports people's lives and health. Hospitals and other medical institutions are required to operate stably 24 hours a day, while pharmaceutical R&D centers and manufacturing facilities must continuously operate clean rooms, precision equipment, air conditioning, and cooling facilities from the standpoint of advanced quality control and safety assurance, all of which require high energy consumption.

The Teijin Group has positioned climate change mitigation and adaptation as one of its materiality issues, and is promoting group-wide reductions with the goal of achieving virtually zero emissions from its own activities (Scope 1+2) by 2050.

Under the Teijin Group's policy, Teijin Pharma has been promoting the reduction of environmental impact in every process from research, development, manufacturing, sales, and disposal. We are continuously working to improve the efficiency of energy use by introducing high-efficiency air conditioning equipment in our manufacturing divisions, converting our sales vehicles to eco-cars, and designing energy-efficient products.

In order to further reduce CO2 emissions (Scope 2) associated with the use of electricity at the R&D center, we have now introduced renewable energy provided by MHI. This is expected to reduce CO2 emissions by approximately 3,343 tons per year at the Tokyo Research Center, contributing to the reduction of Scope 2 at this site.

Yasuhiro Itano, General Manager, Tokyo Research Center, Teijin Pharma Limited Comments
In order to realize our long-term vision, "A Company that Supports Future Society," the Teijin Group has positioned "climate change mitigation and adaptation" as one of the key social issues and is aiming to achieve virtually zero emissions (Scope 1+2) from our own activities by 2050. As the entire Group accelerates its efforts to reduce emissions, the Tokyo Research Center, our R&D center for healthcare business, is steadily reducing CO2 emissions from electricity use (Scope 2), and is also working to meet the Tokyo Metropolitan Government's "Obligation to Reduce Total Greenhouse Gas Emissions and Emissions Trading System," which calls for a reduction to 501 TP3T by FY2025. We also needed to ensure that the reduction rate raised to 50% from FY2025 under the Tokyo Metropolitan Government's "Total Greenhouse Gas Emissions Reduction Obligation and Emissions Trading System.

When decarbonizing electricity, it is essential to ensure both a stable supply and economic rationality. A major deciding factor was the ability of the Resil solution to simultaneously decarbonize and optimize electricity costs.

We believe that the reduction of approximately 3,343 tons of CO2 emissions per year achieved through this initiative is a further step forward in our efforts to reduce our environmental impact, and will help ensure that the Tokyo Research Center fulfills its obligation to reduce its emissions. We will continue our efforts to realize a sustainable society under the Group's policy.

Daiki Koriyama, Executive Officer and General Manager, Green Energy Business Division, ■Regil Corporation Comment
The medical and healthcare fields are the foundation that supports society, and promoting decarbonization while protecting the stable operation of these fields is an important theme. We are honored to be able to contribute to the efforts of the Teijin Group and Teijin Pharma to reduce their environmental impact from the energy field.

This initiative will advance the reduction of Scope 2 at R&D sites in concrete figures. We will continue to contribute to the Teijin Group's efforts to promote decarbonization and support corporate decarbonization through solutions that combine stable supply with the visualization of environmental value.